Progression Free Survival Clinical Trial
Official title:
Preliminary Study of Maintenance Therapy for Patients With Extensive Stage of Small-cell Lung Cancer
This study involves patients treated with cisplatin and etoposide (induction therapy), followed by treatment with a drug called S1 (maintenance therapy). The main purpose of this study is to determine if this type of treatment will delay the growth of the tumor and if so, for how long. The primary endpoint is progression free survival and second endpoints are toxicities, overall survival.
Small cell lung cancer (SCLC) accounts for about 20% of lung cancer, has a high degree of malignancy, short doubling time, early and widespread metastasis, is sensitive to chemotherapy and radiotherapy, and has a high initial response rate, but is prone to secondary drug resistance and relapse. The treatment is mainly based on systemic chemotherapy, and if maintenance therapy with S1 after standard EP regimen induction therapy could prolong progression free survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01453257 -
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
|
Phase 2 | |
| Recruiting |
NCT03748680 -
IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06338683 -
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT03100955 -
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT05477797 -
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
|
N/A | |
| Completed |
NCT02959749 -
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
|
Phase 2/Phase 3 |